The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure DI Group New England Journal of Medicine 336 (8), 525-533, 1997 | 3454 | 1997 |
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases SM Garland, M Hernandez-Avila, CM Wheeler, G Perez, DM Harper, ... New England Journal of Medicine 356 (19), 1928-1943, 2007 | 2496 | 2007 |
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial DM Harper, EL Franco, C Wheeler, DG Ferris, D Jenkins, A Schuind, ... The lancet 364 (9447), 1757-1765, 2004 | 2398 | 2004 |
Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in Young Women: A Randomised Double-Blind Placebo-Controlled Multicentre … Lancet Oncol . 6 (5), 271-8, 2005 | 2363 | 2005 |
Sustained efficacy up to 4· 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial DM Harper, EL Franco, CM Wheeler, AB Moscicki, B Romanowski, ... The Lancet 367 (9518), 1247-1255, 2006 | 2303 | 2006 |
Screening for colorectal cancer: US Preventive Services Task Force recommendation statement K Bibbins-Domingo, DC Grossman, SJ Curry, KW Davidson, JW Epling, ... Jama 315 (23), 2564-2575, 2016 | 1899 | 2016 |
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of … J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ... The Lancet 369 (9580), 2161-2170, 2007 | 1690 | 2007 |
American Cancer Society guideline for the early detection of cervical neoplasia and cancer D Saslow, CD Runowicz, D Solomon, AB Moscicki, RA Smith, HJ Eyre, ... CA: a cancer journal for clinicians 52 (6), 342-362, 2002 | 1500 | 2002 |
2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities wright tc jr JAMA 287, 2120-2129, 2002 | 1372 | 2002 |
Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial D Solomon, M Schiffman, R Tarone Journal of the National Cancer Institute 93 (4), 293-299, 2001 | 1350 | 2001 |
Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study SM Stoler MH JAMA 285 (11), 1500-5, 2001 | 1322 | 2001 |
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors LS Massad, MH Einstein, WK Huh, HA Katki, WK Kinney, M Schiffman, ... Journal of lower genital tract disease 17, S1-S27, 2013 | 1207 | 2013 |
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Bibbins-Domingo K, USPST Force. Ann Intern Med. ; 164 (12), 836-45., 2016 | 985 | 2016 |
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined … EA Joura, S Leodolter, M Hernandez-Avila, CM Wheeler, G Perez, ... The Lancet 369 (9574), 1693-1702, 2007 | 844 | 2007 |
Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force JS Lin, MA Piper, LA Perdue, CM Rutter, EM Webber, E O’Connor, ... Jama 315 (23), 2576-2594, 2016 | 822 | 2016 |
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors D Saslow, PE Castle, JT Cox, DD Davey, MH Einstein, DG Ferris, ... CA: a cancer journal for clinicians 57 (1), 7-28, 2007 | 786 | 2007 |
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 LL Villa, KA Ault, AR Giuliano, RLR Costa, CA Petta, RP Andrade, ... Vaccine 24 (27-28), 5571-5583, 2006 | 682 | 2006 |
Human papillomavirus and HPV vaccines: a review FT Cutts, S Franceschi, S Goldie, X Castellsague, S De Sanjose, ... Bulletin of the World Health Organization 85, 719-726, 2007 | 637 | 2007 |
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis … CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ... The lancet oncology 13 (1), 100-110, 2012 | 628 | 2012 |
2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests TC Wright Jr, LS Massad, CJ Dunton, M Spitzer, EJ Wilkinson, D Solomon American journal of obstetrics and gynecology 197 (4), 346-355, 2007 | 624 | 2007 |